{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000054","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.778059+00:00","generated_at":"2026-06-10T02:06:25.230180+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AnaptysBio reports positive Phase 3 GEMINI-1 trial for imsidolimab in GPP; 53.3% vs 13.3% placebo at Week 4","bullets":["53.3% of imsidolimab-treated patients achieved GPPPGA 0/1 at Week 4 vs 13.3% placebo (p=0.0131).","No SAEs or severe AEs in imsidolimab-treated patients; low infection rate vs placebo.","Only 3.3% had detectable non-neutralizing ADA.","Plans to file BLA with FDA by Q3 2024 and out-license imsidolimab in 2024.","Comprehensive data from GEMINI-1 and top-line GEMINI-2 expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000054","json":"https://secwatch.observer/filing/0001370053-23-000054.json","markdown":"https://secwatch.observer/filing/0001370053-23-000054.md","text":"https://secwatch.observer/filing/0001370053-23-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/0001370053-23-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/anab-20231009.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T02:06:25.230180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}